BioTime Appoints Stephen C. Farrell to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)

Appoints Stephen C. Farrell to Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--March 12, 2013--BioTime, Inc. (NYSE

MKT: BTX) today announced that Stephen C. Farrell has been appointed to

its Board of Directors.

"We are pleased to welcome an experienced executive of Steve's caliber

to BioTime's board," said Alfred D. Kingsley, Chairman of the Board of

BioTime. "Steve adds critical and highly relevant experience as a

successful leader and director of healthcare companies during periods of

rapid growth. His operational and financial experience and his strategic

vision will be valuable additions to our board during an exciting period

of growth for BioTime."

"BioTime's development and progress toward the acquisition of novel

technologies in the stem cell space over the past year, along with its

recent successful financings, have further established it as a leader in

regenerative medicine," said Mr. Farrell. "I am honored to join the

BioTime Board of Directors during such an important time in the

Company's growth, and look forward to contributing to the development of

these new technologies, which have the potential to significantly

improve the health and quality of life of patients around the world."

Mr. Farrell currently serves as Chief Executive Officer and Director of

Convey Health Solutions (formerly known as NationsHealth, Inc.), a

healthcare business process outsourcing company headquartered in

Sunrise, Florida. Convey Health Solutions utilizes both technology and

staff to manage end-to-end insurance processes for business clients.

Previously, he served as President of PolyMedica Corporation, a publicly

traded provider of diabetes supplies and related services that was

acquired in 2007 by Medco Health Solutions in a transaction valued at

$1.5 billion. During his eight year tenure at PolyMedica, Mr. Farrell

served as its President, Chief Operating Officer, Chief Financial

Officer, Chief Compliance Officer, and Treasurer. Mr. Farrell also

served as Executive Vice President and Chief Financial Officer of Stream

Global Services, Inc., a business process outsourcing company. Earlier

in his career, Mr. Farrell served as Senior Manager at

PricewaterhouseCoopers LLP. Mr. Farrell holds an A.B. from Harvard

University, and an M.B.A. from the Darden School at the University of

Virginia. Mr. Farrell currently serves on the board and is chairman of

the Audit Committee of Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a

biopharmaceutical company focused on the treatment of patients with

serious, difficult-to-treat autoimmune and inflammatory disorders.

BioTime, headquartered in Alameda, California, is a biotechnology

company focused on regenerative medicine and blood plasma volume

expanders. Its broad platform of stem cell technologies is enhanced

through subsidiaries focused on specific fields of application. BioTime

develops and markets research products in the fields of stem cells and

regenerative medicine, including a wide array of proprietary PureStem

cell lines, HyStem hydrogels, culture media, and

differentiation kits. BioTime is developing Renevia (formerly

known as HyStem -Rx), a biocompatible,

implantable hyaluronan and collagen-based matrix for cell delivery in

human clinical applications. BioTime's therapeutic product development

strategy is pursued through subsidiaries that focus on specific organ

systems and related diseases for which there is a high unmet medical

need. BioTime's majority-owned subsidiary Cell Cure Neurosciences Ltd.

is developing therapeutic products derived from stem cells for the

treatment of retinal and neural degenerative diseases. BioTime's

subsidiary OrthoCyte Corporation is developing therapeutic applications

of stem cells to treat orthopedic diseases and injuries. Another

subsidiary, OncoCyte Corporation, focuses on the diagnostic and

therapeutic applications of stem cell technology in cancer, including

the diagnostic product PanC-Dx currently being developed for the

detection of cancer in blood samples. ReCyte Therapeutics, Inc. is

developing applications of BioTime's proprietary induced pluripotent

stem cell technology to reverse the developmental aging of human cells

to treat cardiovascular and blood cell diseases. BioTime's subsidiary

LifeMap Sciences, Inc. markets GeneCards , the

leading human gene database, as part of an integrated database suite

that also includes the LifeMap Discovery database of embryonic

development, stem cell research and regenerative medicine, and MalaCards,

the human disease database. LifeMap Sciences also markets BioTime

research products and PanDaTox, an innovative, recently

developed, searchable database that can aid in the discovery of new

antibiotics and biotechnologically beneficial products. BioTime

Acquisition Corporation is a new subsidiary being used to acquire the

stem cell assets of Geron Corporation, including patents and other

intellectual property, biological materials, reagents, and equipment for

the development of new therapeutic products for regenerative medicine.

BioTime's lead product, Hextend , is a blood

plasma volume expander manufactured and distributed in the U.S. by

Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under

exclusive licensing agreements. Additional information about BioTime can

be obtained at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results,

future growth in research, technology, clinical development, and

potential opportunities for BioTime and its subsidiaries, along with

other statements about the future expectations, beliefs, goals, plans,

or prospects expressed by management constitute forward-looking

statements. Any statements that are not historical fact (including, but

not limited to statements that contain words such as "will," "may"

"believes," "plans," "anticipates," "expects," "estimates") should also

be considered to be forward-looking statements. Forward-looking

statements involve risks and uncertainties, including, without

limitation, risks inherent in the development and/or commercialization

of potential products, uncertainty in the results of clinical trials or

regulatory approvals, need and ability to obtain future capital, and

maintenance of intellectual property rights. Actual results may differ

materially from the results anticipated in these forward-looking

statements and as such should be evaluated together with the many

uncertainties that affect the business of BioTime and its subsidiaries,

particularly those mentioned in the cautionary statements found in